Skip to main content
CCCC logo

CCCC · C4 Therapeutics, Inc. · Executive Compensation

Track CCCC — free
$2.48 +0.04 (+1.64%) At close · Nov 20
Market Cap
$325.67M
Shares
131.32M
Volume · Nov 20 3.63M Avg daily vol (3M) 2.55M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Andrew J. Hirsch $2,940,975
Leonard Reyno $1,641,798
Kendra R. Adams $1,476,789
Fiscal 2024
Executive Total
Andrew J. Hirsch $5,239,784
Leonard Reyno $2,314,100
Kendra R. Adams $2,197,489
Fiscal 2023
Executive Total
Andrew J. Hirsch $3,790,099
Leonard Reyno $1,674,727
Stewart Fisher $1,533,917
Kendra R. Adams $1,210,598
Fiscal 2022
Executive Total
Scott N. Boyle $3,914,000
Stewart Fisher $3,104,878
Andrew J. Hirsch $2,595,395
Fiscal 2021
Executive Total
Lauren A. White $4,085,603
Stewart Fisher $3,788,874
Adam S. Crystal $3,564,503
Jolie M. Siegel $3,375,441
Andrew J. Hirsch $952,200
William T. McKee $348,403
Fiscal 2020
Executive Total
Andrew J. Hirsch $20,931,971
Marc A. Cohen $9,132,899
William T. McKee $2,099,745
Adam S. Crystal $1,603,320
Stewart Fisher $1,589,693
Andrew Phillips $618,275
Fiscal 2019
Executive Total
Andrew Phillips $4,193,675
Adam S. Crystal $1,689,946
Stewart Fisher $465,753
Marc A. Cohen —
Andrew J. Hirsch —
William T. McKee —

Executive changes

Person Change Filed
Kendra R. Adams Appointed 2026-05-15
Bruce Downey
“Mr. Downey’s decision not to stand for reelection was not due to any disagreements with the Company on any matter relating to the Company’s strategy, operations, policies or practices.”
Retired 2025-04-14
Steven L. Hoerter Appointed 2024-11-20
Paige Mahaney, Ph.D. Appointed 2024-10-15
Stewart Fisher, Ph.D.
“Dr. Fisher's retirement and pending departure from the Company was not because of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Retired 2024-10-15
Stephen Fawell, Ph.D. Appointed 2024-09-03
Malcolm Salter
“There are no disagreements between Mr. Salter and the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2024-09-03
Bruce Downey Resigned 2024-06-10
Ron Cooper Appointed 2024-06-10
Ron Cooper Appointed 2024-06-10
Glenn Dubin
“There are no disagreements between Mr. Dubin and the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-06-10
Owen P. Hughes, Jr. Appointed 2023-11-20
Mark Mossler Appointed 2023-09-05
Kendra Adams Appointed 2023-09-05
Lauren White
“Ms. White’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles and practices.”
Resigned 2023-09-05
Hagop Youssoufian, M.D. Appointed 2023-02-02
Adam S. Crystal, M.D., Ph.D. Resigned 2023-02-02
Donna Grogan, M.D. Appointed 2022-08-02
Laura Bessen, M.D. Appointed 2022-08-02
Elena Prokupets, Ph.D.
“The resignation was not due to any disagreements with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2022-03-16
Utpal Koppikar Appointed 2022-03-16
William T. McKee Appointed 2021-05-20
Laura J. Wahlberg Resigned 2021-05-20
Lauren White Appointed 2021-05-20
Laura J. Wahlberg Resigned 2021-04-30

Leadership

Key facts CIK 1662579 CUSIP 12529R107 13F (30d) 159 filings 142 filers Visit website Investor relations